Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Hidden regulation of herpes simplex virus 1 pre-mRNA splicing and polyadenylation by virally encoded immediate early gene ICP27.

Tang S, Patel A, Krause PR.

PLoS Pathog. 2019 Jun 17;15(6):e1007884. doi: 10.1371/journal.ppat.1007884. eCollection 2019 Jun.

2.

Herpes Simplex Virus 2 in Autonomic Ganglia: Evidence for Spontaneous Reactivation.

Pieknik JR, Bertke AS, Krause PR.

J Virol. 2019 May 15;93(11). pii: e00227-19. doi: 10.1128/JVI.00227-19. Print 2019 Jun 1.

3.

Towards dynamic monitoring of cell cultures using high throughput sequencing.

McClenahan SD, Krause PR.

Vaccine. 2019 Feb 8;37(7):1001-1005. doi: 10.1016/j.vaccine.2018.12.019. Epub 2019 Jan 11.

PMID:
30642729
4.

Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates.

Vannice KS, Cassetti MC, Eisinger RW, Hombach J, Knezevic I, Marston HD, Wilder-Smith A, Cavaleri M, Krause PR.

Vaccine. 2019 Feb 4;37(6):863-868. doi: 10.1016/j.vaccine.2018.12.040. Epub 2019 Jan 11.

5.

Report of the international conference on next generation sequencing for adventitious virus detection in biologicals.

Khan AS, Benetti L, Blumel J, Deforce D, Egan WM, Knezevic I, Krause PR, Mallet L, Mayer D, Minor PD, Neels P, Wang G.

Biologicals. 2018 Sep;55:1-16. doi: 10.1016/j.biologicals.2018.08.002. Epub 2018 Aug 6.

PMID:
30093175
6.

Evaluating human trials: FDA's role.

Krause PR, Gruber MF.

Science. 2018 Jun 22;360(6395):1308. doi: 10.1126/science.aau0591. Epub 2018 Jun 21. No abstract available.

PMID:
29930128
7.

A VP26-mNeonGreen Capsid Fusion HSV-2 Mutant Reactivates from Viral Latency in the Guinea Pig Genital Model with Normal Kinetics.

Pieknik JR, Bertke AS, Tang S, Krause PR.

Viruses. 2018 May 8;10(5). pii: E246. doi: 10.3390/v10050246.

8.

Herpes Simplex Virus 2 Latency-Associated Transcript (LAT) Region Mutations Do Not Identify a Role for LAT-Associated MicroRNAs in Viral Reactivation in Guinea Pig Genital Models.

Kawamura Y, Bosch-Marce M, Tang S, Patel A, Krause PR.

J Virol. 2018 Jun 29;92(14). pii: e00642-18. doi: 10.1128/JVI.00642-18. Print 2018 Jul 15.

9.

Clinical Development Strategies and Considerations for Zika Vaccine Licensure.

Gruber MF, Farizo KM, Pratt RD, Fink DL, Finn TM, Krause PR, Borio LL, Marks PW.

J Infect Dis. 2017 Dec 16;216(suppl_10):S964-S970. doi: 10.1093/infdis/jix433. Review.

10.

Glutamine supplementation suppresses herpes simplex virus reactivation.

Wang K, Hoshino Y, Dowdell K, Bosch-Marce M, Myers TG, Sarmiento M, Pesnicak L, Krause PR, Cohen JI.

J Clin Invest. 2017 Jun 30;127(7):2626-2630. doi: 10.1172/JCI88990. Epub 2017 Jun 5.

11.

Regulating vaccines at the FDA: development and licensure of Zika vaccines.

Gruber MF, Krause PR.

Expert Rev Vaccines. 2017 Jun;16(6):525-527. doi: 10.1080/14760584.2017.1324304. Epub 2017 May 4. No abstract available.

PMID:
28447498
12.

Herpes simplex virus ICP27 regulates alternative pre-mRNA polyadenylation and splicing in a sequence-dependent manner.

Tang S, Patel A, Krause PR.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12256-12261. Epub 2016 Oct 10.

13.

Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display.

Guo N, Duan H, Kachko A, Krause BW, Major ME, Krause PR.

EBioMedicine. 2015 Jun 30;2(8):859-67. doi: 10.1016/j.ebiom.2015.06.021. eCollection 2015 Aug.

14.

Interim results from a phase 3 Ebola vaccine study in Guinea.

Krause PR.

Lancet. 2015 Aug 29;386(9996):831-3. doi: 10.1016/S0140-6736(15)00002-1. No abstract available.

PMID:
26335862
15.

Approaches to demonstration of Ebola virus vaccine efficacy.

Krause PR, Cavaleri M, Coleman G, Gruber MF.

Lancet Infect Dis. 2015 Jun;15(6):627-9. doi: 10.1016/S1473-3099(15)00027-4. Epub 2015 May 17. No abstract available.

PMID:
26008825
16.

Immunology of protection from Ebola virus infection.

Krause PR, Bryant PR, Clark T, Dempsey W, Henchal E, Michael NL, Regules JA, Gruber MF.

Sci Transl Med. 2015 May 6;7(286):286ps11. doi: 10.1126/scitranslmed.aaa8202. Review.

PMID:
25947159
17.

Characterization of herpes simplex virus 2 primary microRNA Transcript regulation.

Tang S, Bosch-Marce M, Patel A, Margolis TP, Krause PR.

J Virol. 2015 May;89(9):4837-48. doi: 10.1128/JVI.03135-14. Epub 2015 Feb 11.

18.

The potential role of advanced technologies for virus detection in development and regulation of vaccines.

McClenahan SD, Krause PR.

PDA J Pharm Sci Technol. 2014 Nov-Dec;68(6):552-5. doi: 10.5731/pdajpst.2014.01030. No abstract available.

PMID:
25475628
19.

Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.

Hill JM, Quenelle DC, Cardin RD, Vogel JL, Clement C, Bravo FJ, Foster TP, Bosch-Marce M, Raja P, Lee JS, Bernstein DI, Krause PR, Knipe DM, Kristie TM.

Sci Transl Med. 2014 Dec 3;6(265):265ra169. doi: 10.1126/scitranslmed.3010643.

20.

Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing.

McClenahan SD, Uhlenhaut C, Krause PR.

Vaccine. 2014 Dec 12;32(52):7115-21. doi: 10.1016/j.vaccine.2014.10.022. Epub 2014 Oct 27.

PMID:
25454874
21.

Optimization of virus detection in cells using massively parallel sequencing.

McClenahan SD, Uhlenhaut C, Krause PR.

Biologicals. 2014 Jan;42(1):34-41. doi: 10.1016/j.biologicals.2013.11.002. Epub 2013 Dec 3.

PMID:
24309095
22.

Priorities for CMV vaccine development.

Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA.

Vaccine. 2013 Dec 17;32(1):4-10. doi: 10.1016/j.vaccine.2013.09.042. Epub 2013 Oct 13. Review.

23.

Discovery of a bovine enterovirus in alpaca.

McClenahan SD, Scherba G, Borst L, Fredrickson RL, Krause PR, Uhlenhaut C.

PLoS One. 2013 Aug 12;8(8):e68777. doi: 10.1371/journal.pone.0068777. eCollection 2013.

24.

Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing.

Tang S, Guo N, Patel A, Krause PR.

J Virol. 2013 May;87(10):5820-30. doi: 10.1128/JVI.03500-12. Epub 2013 Mar 13.

25.

Use of DOP-PCR in Non-Specific Virus Detection.

Uhlenhaut C, McClenahan S, Krause PR.

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):681-4. doi: 10.5731/pdajpst.2011.00842.

PMID:
22294597
26.

Regulatory approaches for control of viral contamination of vaccines.

McClenahan S, Uhlenhaut C, Krause PR.

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):557-62. doi: 10.5731/pdajpst.2011.00819.

PMID:
22294577
27.

Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia.

Uhlenhaut C, Cohen JI, Pavletic S, Illei G, Gea-Banacloche JC, Abu-Asab M, Krogmann T, Gubareva L, McClenahan S, Krause PR.

Transpl Infect Dis. 2012 Feb;14(1):79-85. doi: 10.1111/j.1399-3062.2011.00657.x. Epub 2011 Jul 12.

28.

Molecular and infectivity studies of porcine circovirus in vaccines.

McClenahan SD, Krause PR, Uhlenhaut C.

Vaccine. 2011 Jun 24;29(29-30):4745-53. doi: 10.1016/j.vaccine.2011.04.087. Epub 2011 May 11.

PMID:
21569811
29.
30.

Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia.

Ohashi M, Bertke AS, Patel A, Krause PR.

J Virol. 2011 Mar;85(6):3030-2. doi: 10.1128/JVI.02426-10. Epub 2010 Dec 15.

31.

Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2.

Umbach JL, Wang K, Tang S, Krause PR, Mont EK, Cohen JI, Cullen BR.

J Virol. 2010 Jan;84(2):1189-92. doi: 10.1128/JVI.01712-09. Epub 2009 Nov 4.

32.

An annual vaccine: seasonal influenza.

Jivapaisarnpong T, Krause PR.

Biologicals. 2009 Nov;37(6):410-1; discussion 421-3. doi: 10.1016/j.biologicals.2009.08.001. Epub 2009 Oct 21.

PMID:
19850497
33.

A vaccine measured with a highly variable assay: rabies.

Jivapaisarnpong T, Schofield T, Krause PR.

Biologicals. 2009 Nov;37(6):412-5; discussion 421-3. doi: 10.1016/j.biologicals.2009.08.002. Epub 2009 Oct 20.

PMID:
19846319
34.

Stability evaluation of vaccines.

Schofield T, Krause PR.

Biologicals. 2009 Nov;37(6):355. doi: 10.1016/j.biologicals.2009.09.001. Epub 2009 Sep 26. No abstract available.

PMID:
19783158
35.

Goals of stability evaluation throughout the vaccine life cycle.

Krause PR.

Biologicals. 2009 Nov;37(6):369-78; discussion 421-3. doi: 10.1016/j.biologicals.2009.08.015. Epub 2009 Sep 22. Review.

PMID:
19775911
36.

Latency-associated transcript (LAT) exon 1 controls herpes simplex virus species-specific phenotypes: reactivation in the guinea pig genital model and neuron subtype-specific latent expression of LAT.

Bertke AS, Patel A, Imai Y, Apakupakul K, Margolis TP, Krause PR.

J Virol. 2009 Oct;83(19):10007-15. doi: 10.1128/JVI.00559-09. Epub 2009 Jul 29.

37.

Investigation of the mechanism by which herpes simplex virus type 1 LAT sequences modulate preferential establishment of latent infection in mouse trigeminal ganglia.

Imai Y, Apakupakul K, Krause PR, Halford WP, Margolis TP.

J Virol. 2009 Aug;83(16):7873-82. doi: 10.1128/JVI.00043-09. Epub 2009 Jun 3.

38.

Use of a universal virus detection assay to identify human metapneumovirus in a hematopoietic stem cell transplant recipient with pneumonia of unknown origin.

Uhlenhaut C, Cohen JI, Fedorko D, Nanda S, Krause PR.

J Clin Virol. 2009 Apr;44(4):337-9. doi: 10.1016/j.jcv.2009.01.011. Epub 2009 Feb 27.

39.
40.

An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor.

Tang S, Bertke AS, Patel A, Wang K, Cohen JI, Krause PR.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10931-6. doi: 10.1073/pnas.0801845105. Epub 2008 Aug 4.

41.

Universal virus detection by degenerate-oligonucleotide primed polymerase chain reaction of purified viral nucleic acids.

Nanda S, Jayan G, Voulgaropoulou F, Sierra-Honigmann AM, Uhlenhaut C, McWatters BJ, Patel A, Krause PR.

J Virol Methods. 2008 Sep;152(1-2):18-24. doi: 10.1016/j.jviromet.2008.06.007. Epub 2008 Jul 16.

PMID:
18601953
42.

Virus assay using antibody-functionalized peptide nanotubes.

MacCuspie RI, Banerjee IA, Pejoux C, Gummalla S, Mostowski HS, Krause PR, Matsui H.

Soft Matter. 2008;4(4):833-839. doi: 10.1039/b714470a. Epub 2008 Feb 22.

43.

Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.

Lane JW, Rehak NN, Hortin GL, Zaoutis T, Krause PR, Walsh TJ.

Clin Chim Acta. 2008 Jan;387(1-2):145-9. Epub 2007 Aug 30.

45.
46.

Development of herpes simplex virus disease in patients who are receiving cidofovir.

Wyles DL, Patel A, Madinger N, Bessesen M, Krause PR, Weinberg A.

Clin Infect Dis. 2005 Sep 1;41(5):676-80. Epub 2005 Jul 26.

PMID:
16080090
47.

Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child.

Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR.

J Infect Dis. 2003 Oct 1;188(7):954-9. Epub 2003 Sep 26.

PMID:
14513413
48.

Pharmacoepidemiologic implications of erroneous varicella vaccinations in pregnancy through confusion with Varicella zoster immune globulin.

Wise RP, Braun MM, Seward JF, Mootrey GT, Shields KE, Salive ME, Krause PR.

Pharmacoepidemiol Drug Saf. 2002 Dec;11(8):651-4.

PMID:
12512240
49.

Live oral poliovirus vaccines and simian cytomegalovirus.

Sierra-Honigmann AM, Krause PR.

Biologicals. 2002 Sep;30(3):167-74.

PMID:
12217341
50.

Supplemental Content

Loading ...
Support Center